05.03.2013 Views

national-clinical-guidelines-for-stroke-fourth-edition

national-clinical-guidelines-for-stroke-fourth-edition

national-clinical-guidelines-for-stroke-fourth-edition

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

5.8 Treatment of unusual causes of <strong>stroke</strong><br />

In about 25% of <strong>stroke</strong> cases, and more commonly in younger patients, no cause is<br />

evident on initial screening. Other causes that should be considered include<br />

paroxysmal atrial fibrillation, which may require 3- or 7-day cardiac monitoring to<br />

detect, intracranial arterial disease, cervical artery dissection, antiphospholipid<br />

syndrome and other prothrombotic conditions, and patent <strong>for</strong>amen ovale (PFO). In<br />

patients where no cause is identified and particularly where there is a history of<br />

venous or arterial thrombosis or early miscarriage, a thrombophilia screen should be<br />

per<strong>for</strong>med.<br />

5.8.1 Vertebral artery disease<br />

5.8.1.1 Recommendation<br />

5.8.1.2 Source<br />

A Angioplasty and stenting of the vertebral artery should only be per<strong>for</strong>med in the<br />

context of a <strong>clinical</strong> trial.<br />

A Consensus<br />

5.8.2 Intracranial arterial disease<br />

5.8.2.1 Recommendations<br />

5.8.2.2 Source<br />

A Patients with symptomatic intracranial stenosis should be offered an intensive<br />

antiplatelet regime (eg aspirin and clopidogrel) <strong>for</strong> 3 months in addition to usual<br />

recommendations <strong>for</strong> secondary prevention intervention and lifestyle modification.<br />

B Endovascular intervention <strong>for</strong> intracranial stenosis should not be per<strong>for</strong>med except in<br />

the context of a <strong>clinical</strong> trial.<br />

A–B Chimowitz et al 2011<br />

5.8.3 Patent <strong>for</strong>amen ovale<br />

Evidence to recommendation<br />

5 Secondary prevention<br />

Patent <strong>for</strong>amen ovale is found in 25% of the healthy population and it is there<strong>for</strong>e difficult<br />

to know whether the finding of a PFO is relevant in a patient with cryptogenic <strong>stroke</strong>. It is<br />

more likely if there is a good history of the <strong>stroke</strong> occurring during or shortly after a<br />

Valsalva manoeuvre or where there are recurrent <strong>stroke</strong>s in different arterial territories. No<br />

adequate trials have been per<strong>for</strong>med to indicate whether treatment should be antiplatelet<br />

drugs, anticoagulation or closure of the PFO. Natural history studies would suggest a low<br />

recurrence rate that probably does not justify the risk of closure unless there is recurrent<br />

© Royal College of Physicians 2012 75

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!